RVX-sCPD9
Phase 1- Indications
- COVID-19
Company intelligence / Profile preview
Swiss Rockets AG
Basel, Basel-Stadt, Switzerlandswissrockets.com ↗
- Ownership
- Private
- Employees
- ~34
- Development stage
- Phase 2
01
Overview
Lead candidate bimiralisib in Phase II for actinic keratosis showed interim results with a full or partial lesion clearance rate of ~60%. Rocketvax’s COVID‑19 nasal spray vaccine demonstrated superior efficacy to mRNA vaccines in animal studies. Other programs are at preclinical or early clinical stages.
- Therapeutic areas
- OncologyDermatologyImmunologyInfectious Diseases
- Modalities
- Small molecules (PI3K/mTOR inhibitors)Radioligand therapies (e.g., Terbium‑161)Vaccines (live attenuated, next-generation platforms)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Emergent BioSolutions—strategic investment/manufacturing/commercialization partnership for four Rocketvax candidates in the US marketNIH—letter of intent under Project NextGen initiative with Rocketvax for next-gen COVID–19 vaccine trial support
Beyond the preview
Go deeper on Swiss Rockets AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Swiss Rockets AG.